COVID-19 vaccine and immune response

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; βCoV), the causative agent of coronavirus disease 2019 (COVID-19), causes severe lower respiratory tract infections and acute respiratory failure syndrome (ARDS). Deaths due to the ongoing COVID-19 pandemic for more than a year are still seen worldwide. Therefore, vaccine trials have gained importance. The discovery of the genome and protein structure of SARS-CoV-2 in a short time allowed the development of nucleic acid-based vaccines (mRNA and DNA vaccines), vector vaccines, inactivated virus vaccines, protein-based vaccines, virus-like particle vaccines, and live attenuated virus vaccines. Many companies, universities, and institutes around the world continue to develop effective vaccines against SARS-CoV-2. In this review, the structural features, classification, genome, and intracellular entry of SARS-CoV-2 coronaviruses, stimulation of the immune system and immunity, COVID-19 vaccine types, and the latest status of clinical trials of these vaccines have been reviewed.

Keywords

COVID-19 / vaccine / immune response

References

[1] Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. J Med Virol. 2020; 92: 424-32.

[2] Salute MD. Nuovo coronavirus [Internet]. Roma: I: Governo-Repubblica Italiana; 2020. c2021 [cited 2021 May 5]. Available from: http://www.salute.gov.it/nuovocoronavirus

[3] Del Rio C, Malani PN. 2019 novel coronavirus-important information for clinicians. JAMA. 2020; 323: 1039-40.

[4] Salute MD. Covid-19-Situazione in Italia [Internet]. Roma: I: Governo-Repubblica Italiana; 2020. c2021 [cited 2021 May 5]. Available from: http://www.salute.gov.it/portale/nuovocoronavirus/dettaglioContenutiNuovoCoronavirus.jsp?lingua=italiano&id=5351&area=nuovoCoronavirus&menu=vuoto

[5] Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak-an update on the status. Mil Med Res. 2020; 7: 11.

[6] Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020; 92: 418-23.

[7] World Health Organization [Internet]. WHO coronavirus (COVID-19) dashboard, 2021. [cited 2021 May 5]. Available from: https://covid19.who.int/

[8] Mavi D, İǚnkaya AÇ. COVID-19: immün patogenez. FLORA. 2020; 25. Turkce.

[9] Masihi KN. Fighting infection using immunomodulatory agents. Expert Opin Biol Ther. 2001; 1: 641-53.

[10] Ou X, Liu Y, Lei X. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 11: 1620.

[11] Kahraman EP, Altındis M. COVID-19 asıları; pandemide sona dogru? J Biotechnol and Strategic Health Res. 2020; 4: 240-9. Turkce.

[12] Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 14: 1011-9.

[13] Yi Y, Lagniton PN, Ye S, Li E, Xu RH. COVID-19: what has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci. 2020; 16: 1753-66.

[14] Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VY, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020; 14: 3822-35.

[15] Kannan S, Ali PSS, Sheeza A, Hemalatha K. COVID-19 (novel coronavirus 2019)-recent trends. Eur Rev Med Pharmacol Sci. 2020; 24: 2006-11.

[16] Baloch S, Baloch MA, Zheng T, Pei X. The coronavirus disease 2019 (COVID-19) pandemic. Tohoku J Exp Med. 2020; 250: 271-8.

[17] Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z, et al. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020; 35: 1545-9.

[18] Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020; 13: 667-73.

[19] Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020; 12: 372.

[20] Hindistan S, Kazak A. Vaccination studies against COVID-19 agent: current status. Bezmialem Science. 2020; 8: 145-52.

[21] Weiss SR, Leibowitz JL. Coronavirus pathogenesis. Adv Virus Res. 2011; 81: 85-164.

[22] Lissenberg A, Vrolijk MM, van Vliet AL, Langereis MA, de Groot-Mijnes JD, Rottier PJ, et al. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hem agglutinin esterase protein display reduced fitness in vitro . J Virol. 2005; 79: 15054-63.

[23] Graham RL, Baric RS . Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol. 2010; 84: 3134-46.

[24] De Haan CA, de Wit M, Kuo L, Montalto-Morrison C, Haagmans BL, Weiss SR, et al. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain . Virology. 2003; 312: 395-406.

[25] Ruch TR, Machamer CE. The coronavirus E protein: assembly and beyond. Viruses. 2012; 4: 363-82.

[26] Escors D, Ortego J, Enjuanes L. The membrane M protein of the transmissible gastroenteritis coronavirus binds to the internal core through the carboxy-terminus. Adv Exp Med Biol. 2001; 494: 589-93.

[27] Khailany AR, Safdar M, Ödžzaslan M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020; 19: 100682.

[28] Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc Natl Acad Sci U S A. 2009; 106: 5871-6.

[29] Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417-8.

[30] Magro C, Mulvey JJ, Berlin D, Nuovo G, Salvatore S, Harp J, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res. 2020; 220: 1-13.

[31] Zhang Y, Geng X, Tan Y, Li Q, Xu C, Xu J, et al. New understanding of the damage of SARS-CoV-2 infection outside the respiratory system. Biomed Pharmacother. 2020; 127: 110195.

[32] Yip MS, Leung HL, Li PH, Cheung CY, Dutry I, Li D, et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J. 2016; 22 Suppl 4: 25-31.

[33] Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 2014; 451: 208-14.

[34] Liu J, Wu P, Gao F, Qi J, Kawana-Tachikawa A, Xie J, et al. Novel immunodominant peptide presentation strategy: a featured HLAA*2402-restricted cytotoxic T-lymphocyte epitope stabilized by intrachain hydrogen bonds from severe acute respiratory syndrome coronavirus nucleocapsid protein. J Virol. 2010; 84: 11849-57.

[35] Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020; 71: 2027-34.

[36] Menachery VD, Schäfer A, Burnum-Johnson KE, Mitchell HD, Eisfeld AJ, Walters KB, et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A. 2018; 115: E1012-21.

[37] Okba NMA, Müller MA, Li W, Wang C, GeurtsvanKessel CH, Corman VC, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients. Emerg Infect Dis. 2020; 26: 1478-88.

[38] Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 2020; 52: 971-7.e3.

[39] Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Elliot J, Hofman C, Hausner MA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild COVID-19. N Engl J Med. 2020; 383: 1085-7.

[40] Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med. 2020; 26: 1200-4.

[41] Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, et al. Humoral immune response to SARS-CoV-2 in Iceland. N Engl J Med. 2020; 383: 1724-34.

[42] Lee JS, Kim SY, Kin TS, Hong KH, Ryoo NH, Lee J, et al. Evidence of severe acute respiratory syndrome coronavirus 2 reinfection after recovery from mild coronavirus disease 2019. Clin Infect Dis. 2020; 73: e3002-8.

[43] Carillo J, Izquierdo-Useros N, Avila-Nieto C, Pradenas E, Clotet B, Blanco J. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2021; 538: 187-91.

[44] Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020; 181: 1489-501.e15.

[45] Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584: 457-62.

[46] Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2 reactive T cells in healthy donors and patients with COVID-19. Nature. 2020; 587: 270-4.

[47] Sekine T, Perez-Potti A, Rivera-Ballesteros O, Strålin K, Gorin JB, Olsson A, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020; 183: 158-68.e14.

[48] Gallais F, Velay A, Nazon C, Wendling MJ, Partisani M, Sibilia J, et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg Infect Dis. 2021; 27: 113-21.

[49] Azalp A. COVID-19 vaccines: light at the end of the tunnel. Archives Medical Review Journal. 2020; 9: 94-100.

[50] World Health Organization [Internet]. COVID-19 vaccine tracker and landscape. [cited 2021 May 16]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines

[51] Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020; 396: 1595-606.

[52] Polack FP, Thomas SJ, Kitchin N, Ablason J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020; 383: 2603-15.

[53] World Health Organization [Internet]. Background document on the mRNA vaccine BNT162b2 (Pfizer/BioNTech) against Covid-19. c2021 [cited 2021 May 17]. Available from: https://www.who.int/publications/i/item/background-document-on-mrna-vaccine-bnt162b2-(pfizer-biontech)-against-covid-19

[54] Shimabukoro T, Nair N. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine. JAMA. 2021; 325: 780-1.

[55] Baden LR, El Sahyl HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021; 384: 403-16.

[56] Centers for Disease Kontrol and Prevention [Internet]. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna Covid-19 vaccine-United States, December 21, 2020-January 20, 2021. [cited 2021 Jun 25]. Available from: https://www.cdc.gov/mmwr/volumes/70/wr/mm7004e1.htm?s_cid=mm7004e1_w

[57] World Health Organization [Internet]. Interim recommendations for use of the Moderna mRNA-1273 vaccine against Covid-19. c2021 [cited 2021 Jun 25]. Available from: https://www.who.int/publications/i/item/interim-recommendations-for-use-of-the-moderna-mrna-1273-vaccine-against-covid-19

[58] Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020; 580: 576-7.

[59] Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK. Lancet. 2021; 397: 99-111.

[60] Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395: 1845-54.

[61] Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost Covid-19 vaccine in two formulations: two open, non-randomised phase 1/2studies from Russia. Lancet. 2020; 396: 887-97.

[62] Logunov DY, Dolzhikova IV, Shcheblyakov D, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector based heterologous prime-boost Covid-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021; 397: 671-81.

[63] Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021; 384: 1824-35.

[64] jnj.com [Internet]. Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use-first single-shot vaccine in fight against global pandemic. c1997- 2021 [cited 2021 Jun 26]. Available from: https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic

[65] World Health Organization [Internet]. The Janssen Ad26.COV2.S COVID-19 vaccine: what you need to know. c2021 [cited 2021 Jun 16]. Available from: https://www.who.int/news-room/feature-stories/detail/the-j-j-covid-19-vaccine-what-you-need-to-know

[66] Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healty adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21: 181-92.

[67] Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healty adults aged 60 years and older: a randomised, double-blind, plasebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021; 21: 803-12.

[68] T.C Sağlık Bakanlığı [Internet]. COVID-19 aşısı bilgilendirme platformu. c2021 [cited 2021 May 13]. Available from: https://covid19asi.saglik.gov.tr/TR-77693/covid-19-asisi.html

[69] Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2020; 21: 39-51.

[70] World Health Organization [Internet]. The Sinopharm COVID-19 vaccine: what you need to know. [cited 2021 May 5]. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know

[71] Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021; 21: 950-61.

[72] Mammen P Jr., Tebas P, Agnes J, Giffear M, Kraynyak KA, Blackwood E, et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv 21256652 [Preprint]. c2021 [cited 2021 May 20]. Available from: https://doi.org/10.1101/2021.05.07.21256652

[73] Mahase E. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant. BMJ. 2021; 372: n296.

[74] ir.novavax.com [Internet]. Novavax: Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. [cited 2021 Jun 25]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3

[75] Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21: 1107-19.

[76] Gobeil P, Pillet S, Séguin A, Boulay I, Mahmood A, Vinh DC, et al. Phase 2 randomized trial of an AS03 adjuvanted plant-based virus-like particle vaccine for Covid-19 in healthy adults, older adults and adults with comorbidities. medRxiv 21257248 [Preprint]. c2021 [cited 2021 May 25]. Available from: https://doi.org/10.1101/2021.05.14.21257248